Notably, GCKR mRNA expression is significantly reduced in patients with severe hepatic steatosis compared to those with mild steatosis [48], highlighting the need for further research to identify pathogenic GCKR variants and elucidate their role in NAFLD pathogenesis. This evidence concerns the gene GCKR and metabolic dysfunction-associated steatotic liver disease.